Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The RTOG Outcomes Model: economic end points and measures.

Andre Konski1, Deborah Watkins-Bruner,

  • 1Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. a-konski@fccc.edu

Expert Opinion on Pharmacotherapy
|March 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

A phase 1 dual-dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer.

Cancer·2025
Same author

Erratum to: Gondi V, Deshmukh S, Brown PD, et al. Sustained Preservation of Cognition and Prevention of Patient-Reported Symptoms With Hippocampal Avoidance During Whole-Brain Radiation Therapy for Brain Metastases: Final Results of NRG Oncology CC001. Int J Radiat Oncol Biol Phys. 2023;117:571-580.

International journal of radiation oncology, biology, physics·2025
Same author

Financial Improvements From Short Course Adjuvant Vaginal Cuff Brachytherapy in Early Endometrial Cancer Compared With Standard of Care, "SAVE" Trial.

Practical radiation oncology·2024
Same author

Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2024
Same author

Acute hospitalizations after proton therapy versus intensity-modulated radiotherapy for locally advanced non-small cell lung cancer in the durvalumab era.

Cancer·2024
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

CURRENT ADVANCES IN PHARMACOTHERAPEUTIC STRATEGIES FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS.

Expert opinion on pharmacotherapy·2026
Same journal

Emerging synthetic drugs for the management of hidradenitis suppurativa: a comprehensive update.

Expert opinion on pharmacotherapy·2026
See all related articles

The Radiation Therapy Oncology Group developed an Outcomes Model to assess clinical trials, focusing on economic impact. Economic analyses show that certain cancer treatments offer cost-effective value for patients.

Area of Science:

  • Health Economics
  • Oncology
  • Clinical Trial Analysis

Background:

  • Economic evaluations are crucial for understanding the value of clinical trials.
  • The Radiation Therapy Oncology Group (RTOG) established an Outcomes Model to assess clinical, humanistic, and economic endpoints.
  • The RTOG Economic Impact Committee was formed in 1994 to analyze the economic implications of cancer clinical trials.

Purpose of the Study:

  • To detail the evolution of economic analyses within the RTOG Outcomes Model.
  • To demonstrate the application of economic evaluations to RTOG clinical trials for various cancers.
  • To inform clinicians and policymakers about the economic value of new cancer treatments.

Main Methods:

  • Evolution from average cost-utility analysis to sophisticated Monte Carlo simulation of Markov models.

Related Experiment Videos

  • Incorporation of prospective economic analyses as an initial endpoint in clinical trials.
  • Economic analyses performed on RTOG trials for non-small cell lung cancer, head and neck cancer, and prostate cancer.

    • Main Results:

    • Concurrent chemotherapy and radiation for non-small cell lung cancer is economically acceptable when considering quality-adjusted survival.
    • More aggressive radiation fractionation schedules for head and neck cancer are within acceptable economic recommendations.
    • The addition of hormone therapy to radiation for prostate cancer is also found to be economically acceptable.

    Conclusions:

    • RTOG's economic analyses provide valuable insights into the cost-effectiveness of cancer treatments.
    • The developed Outcomes Model comprehensively assesses the triad of clinical, humanistic, and economic endpoints.
    • Economic evaluations inform decision-making regarding the adoption of new or improved cancer therapies.